Welcome to our dedicated page for GYRE THERAPEUTICS SEC filings (Ticker: GYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gyre Therapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with U.S. and China operations, revenue from Gyre Pharmaceuticals, and a pipeline centered on anti-fibrotic therapies and targeted protein degradation assets. Form 8-K reports cover operating results, business updates, CDE/NMPA regulatory disclosures for F351, and clinical-program updates for Hydronidone and pirfenidone.
Proxy and material-event filings describe governance matters, shareholder voting items, material agreements, capital-structure disclosures and the completed Cullgen acquisition, including preferred-stock and common-stock conversion mechanics. The record also includes Regulation FD disclosures addressing commercial products, research spending and pipeline development.
Gyre Therapeutics, Inc., a commercial-stage biopharmaceutical company, reported revenue of $29,105 and $53,535 for the three and six months ended June 30, 2026, respectively (amounts in thousands). On May 4, 2026 it completed a common-control merger with Cullgen Inc., now a wholly owned subsidiary, and earlier periods have been retrospectively recast.
Operating expenses reached $43,468 in the quarter, including research and development of $14,300, related-party R&D of $4,836, selling and marketing of $13,754, and general and administrative of $7,867, plus transaction costs. Net loss attributable to common stockholders was $11,663 for the quarter and $24,809 year-to-date, compared with a $2,044 net loss and $126 of net income in the comparable 2025 periods, with basic and diluted loss per share of $0.12 and $0.26 for the three- and six‑month periods. Cash and cash equivalents were $43,287, alongside short-term bank deposits, short-term investments, and long-term certificates of deposit that supported total assets of $199,255 and equity of $142,489. Management states that existing liquidity, operating cash flows, and access to capital markets are expected to fund operations for at least twelve months. Revenue is concentrated in mainland China, with Sinopharm and two other distributors accounting for most pharmaceutical product sales, and a single partner generating all collaboration-based revenue.
Gyre Therapeutics reported Q2 2026 revenue of $29.1 million, down 2% from Q2 2025, and GAAP basic EPS of $(0.12). Net loss widened to $14.3 million from a $2.2 million loss, while non-GAAP adjusted net loss was $12.2 million versus $0.6 million a year earlier.
For the first half of 2026, revenue was $53.5 million compared with $60.3 million in 2025, with net loss of $32.8 million versus net income of $2.7 million. Cash, deposits, investments and long-term certificates of deposit totaled $103.2 million as of June 30, 2026. Financial statements were retrospectively recast to treat Gyre and Cullgen as entities under common control.
Key developments included completion of an all-stock acquisition of Cullgen valued at about $300 million, acceptance by China’s CDE of the NDA for F351 for CHB-induced liver fibrosis, continued growth of pirfenidone sales to $28.0 million in Q2, and expanded R&D spending, including F351 Phase 3C costs and milestone payments.
Gyre Therapeutics director Claire Weston received a grant of stock options to purchase 40,000 shares of common stock at an exercise price of $6.11 per share. The options vest in 36 equal monthly installments through August 3, 2029 and expire on August 3, 2036, leaving her with options on 40,000 shares.
Gyre Therapeutics director Kirkby Maxwell received a grant of stock options covering 40,000 shares of common stock on August 3, 2026. The options have a $6.1100 exercise price, expire on August 3, 2036, and vest in 36 equal monthly installments through August 3, 2029, subject to continued service.
GYRE THERAPEUTICS, INC. filed an initial Form 3 reporting the beneficial ownership status of director Weston Claire. The report lists Weston Claire as a director but shows no reported transactions or share holdings at this time. The remarks reference Exhibit 24, a Power of Attorney authorizing filings.
Gyre Therapeutics, Inc. reported an initial statement of beneficial ownership for Kirkby Maxwell. He is identified as a director, not an officer or 10% owner, and currently has no reportable securities holdings or transactions. Remarks reference an Exhibit 24 Power of Attorney.
Gyre Therapeutics, Inc. appointed three new members to its board of directors, effective August 1, 2026: Yue Xiong, Ph.D., the company’s Chief Scientific Officer, as a Class I director; Maxwell Kirkby as a Class II director; and Claire Weston, Ph.D., as a Class III director. Mr. Kirkby joins the Compensation Committee and Dr. Weston joins the Audit Committee. Mr. Kirkby and Dr. Weston each receive an initial stock option grant covering 40,000 shares of common stock, vesting in equal monthly installments over three years, plus cash compensation under the non-employee director policy. Dr. Xiong, who already serves as Chief Scientific Officer and is party to the standard indemnification agreement, will receive no additional compensation for board service.
Gyre Therapeutics, Inc. filed Amendment No. 1 to a current report to add audited and interim financial statements for its newly acquired subsidiary Cullgen Inc. and unaudited pro forma condensed combined financials following their all-stock merger valuing Cullgen at approximately $300 million.
Cullgen generated $15,373 (in thousands) of collaboration revenue in 2025, primarily from an Astellas agreement, and recorded a net loss of $10,805 (in thousands), driven by research and development expenses of $19,330 (in thousands) and general and administrative expenses of $10,246 (in thousands). Year-end cash and cash equivalents were $12,122 (in thousands) with short-term investments of $28,085 (in thousands).
For the three months ended March 31, 2026, Cullgen reported collaboration revenue of $1,911 (in thousands) versus $8,513 (in thousands) a year earlier and a net loss of $8,719 (in thousands), leading to an accumulated deficit of $144,834 (in thousands). Management states that existing cash, cash equivalents and short-term investments are expected to fund operations for at least 12 months, while the company continues to anticipate ongoing operating losses.
Gyre Therapeutics, Inc., a commercial-stage biopharmaceutical company, filed a pre-effective amendment to its Form S-3 to register up to 31,302,863 shares of common stock for resale by existing stockholders, increasing the original 30,221,531-share registration by 1,081,332 shares.
The Resale Shares comprise 11,735,356 merger shares issued in the Cullgen acquisition, 18,486,175 shares issuable upon conversion of 3,697,235 Series B Preferred Shares, 540,666 PIPE shares, and 540,666 shares issuable upon conversion of Series X Preferred Stock via a warrant. Gyre will not receive proceeds from stockholder resales, and will receive cash only if the warrant is exercised for cash at $4,915.00 per share.
Common stock outstanding was 111,488,849 shares as of May 31, 2026, a baseline figure, not the amount being registered. The company highlights significant PRC-related legal and regulatory risks, HFCAA-driven audit and potential delisting risks, and notes that entities affiliated with GNI Japan would retain a majority stake even if all their registered shares are sold.